| [15] |
Kwee RM, Kwee TC. Modern imaging techniques for preoperative detection ofdistant metastases in gastric cancer [J]. World J Gastroenterol, 2015, 21(37):10502-10509.
|
| [16] |
Wang Z, Chen JQ. Imaging in assessing hepatic and peritoneal metastases of gastric cancer : a systematic review [J]. BMC Gastroenterol, 2011,11:19.
|
| [17] |
Yajima K, Kanda T, Ohashi M, et al. Clinical and diagnostic significance of preoperative computed tomography findings of ascites in patients with advanced gastric cancer [J]. Am J Surg, 2006,192(2):185-190.
|
| [18] |
Kim SJ, Kim HH, Kim YH, et al. Peritoneal Metastasis : Detection with 16- or 64-Detector Row CT in Patients Undergoing Surgery for Gastric Cancer [J]. Radiology, 2009, 253(2):407-415.
|
| [19] |
严超，朱正纲，燕敏，等.多排CT对胃癌腹膜转移术前预测的单中心大宗病例研究[J].中华胃肠外科杂志，2010，13(2):106-110.
|
| [20] |
Chang DK, Kim JW, Kim BK, et al. Clinical significance of CT-defined minimal ascites in patients with gastric cancer[J]. World J Gastroenterol, 2005, 11(42):6587-6592.
|
| [21] |
Fehniger J, Thomas S, Lengyel E, et al. A prospective study evaluating diffusion weighted magnetic resonance imaging ( DW-MRI) in the detection of peritoneal carcinomatosis in suspected gynecologic malignancies [J]. Gynecol Oncol, 2016, 142(1):169-175.
|
| [22] |
周鹏，曲辉，史惠文，等.血清糖类抗原125对胃癌腹膜转移及其预后的预测价值[J].中华胃肠外科杂志，2014，17(10):1027-1030.
|
| [23] |
Lai H, Jin Q, Lin Y, et al. Combined use of lysyl oxidase, carcino-embryonic antigen, and carbohydrate antigens improves the sensitivityof biomarkers in predicting lymph node metastasis and peritoneal metastasis in gastric cancer [J]. Tumour Biol, 2014,35(10):10547-10554.
|
| [24] |
Emoto S, Ishigami H, Yamashita H, et al. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination [J]. Gastric Cancer, 2012,15(2):154-161.
|
| [25] |
Nakata B, Hirakawa-YS Chung K, Kato Y, et al. Serum CA 125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma [J]. Cancer, 1998,83(12):2488-2492.
|
| [26] |
Hwang GI, Yoo CH, Sohn BH, et al. Predictive value of preoperative serum CEA, CA19-9 and CA125 levels for peritoneal metastasis in patients with gastric carcinoma [J]. Cancer Res Treat, 2004,36(3):178-181.
|
| [27] |
张永乐，薛英威，蓝秀文，等.肿瘤标记物CA19-9、CEA对胃癌转移和预后预测价值的分析[J].哈尔滨医科大学学报，2010，44(2):181-184, 188.
|
| [28] |
National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Gastric Cancer Version 3.2015. US. 23 March 2015.
|
| [29] |
Li Z, Ji J. Application of laparoscopy in the diagnosis and treatment of gastric cancer [J]. Ann Transl Med, 2015,3(9):126.
|
| [30] |
Lee SD, Ryu KW, Eom BW, et al. Prognostic significance of peritoneal washing cytology in patients with gastric cancer [J]. Br J Surg, 2012,99(3):397-403.
|
| [31] |
Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma (The 14th Edition) [M].金原出版株式会社，March 2010.
|
| [32] |
Yonemura Y, Elnemr A, Endou Y, et al. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer [J]. World J Gastrointest Oncol, 2010,2(2):85-97.
|
| [33] |
De Andrade JP, Mezhir JJ. The critical role of peritoneal cytology in the staging of gastric cancer : an evidence-based review [J]. J Surg Oncol, 2014,110(3):291-297.
|
| [34] |
Yoo CH, Noh SH, Shin DW, et al. Recurrence following curative resection for gastric carcinoma [J]. Br J Surg, 2000, 87(2):236-242.
|
| [35] |
Tanaka T, Kumagai K, Shimizu K, et al. Peritoneal metastasis in gastric cancer with particular reference to lymphatic advancement; Extranodal invasion is a significant risk factor for peritoneal metastasis [J]. J Surg Oncol, 2000, 75(3):165-171.
|
| [36] |
Huang B, Sun Z, Wang Z, et al. Factors associated with peritoneal metastasis in non-serosa-invasive gastric cancer: a retrospective study of a prospectively-collected database [J]. BMC Cancer, 2013,13:57.
|
| [37] |
Esaki Y, Hirayama R, Hirokawa K. A comparison of patterns of metastasis in gastric cancer by histologic type and age [J]. Cancer, 1990,65(9):2086-2090.
|
| [38] |
季加孚.胃肠道恶性肿瘤外科的无瘤技术和原则[J].中国实用外科杂志，2005，25(4):254-256.
|
| [39] |
Oshima T, Yamada R, Hatori S, et al. Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer [J]. Oncol Rep, 2006,16(2):361-366.
|
| [40] |
Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase Ⅲ trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage Ⅱ or Ⅲ gastric cancer [J]. J Clin Oncol, 2011,29(33):4387-4393.
|
| [41] |
Kanda M, Murotani K, Kobayashi D, et al. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors amongpatients with stage Ⅱ/Ⅲ gastric cancer : a propensity score matching analysis [J]. Surgery, 2015, 158(6):1573-1580.
|
| [42] |
Tsuburaya A, Yoshida K, Kobayashi M, et al. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT) : a phase 3 factorial randomised controlled trial [J]. Lancet Oncol, 2014,15(8):886-893.
|
| [43] |
Takahari D, Hamaguchi T, Yoshimura K, et al. Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage Ⅲgastric cancer[J]. Gastric Cancer, 2014, 17(2):383-386.
|
| [44] |
Fujitani K, Tamura S, Kimura Y, et al. Three-year outcomes of a phase Ⅱ study of adjuvant chemotherapy with S-1 plus docetaxel for stage Ⅲ gastriccancer after curative D2 gastrectomy [J]. Gastric Cancer, 2014,17(2):348-353.
|
| [45] |
Yoon S, Yoo C, Ryu MH, et al. Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curativelyresected stage Ⅲ B-Ⅳ gastric cancer [J]. Gastric Cancer, 2017, 20(1):182-189.
|
| [1] |
Globocan 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 [EB/OL] WHO: International Agency for Research on Cancer. [Accessed 8 April 2016].
URL
|
| [2] |
Shen L, Shan YS, Hu HM, et al. Management of gastric cancer in Asia: resource-stratified guidelines [J]. Lancet Oncol, 2013, 14(12):e535-e547.
|
| [3] |
Nashimoto A, Akazawa K, Isobe Y, et al. Gastric cancer treatedin 2002 in Japan: 2009 annual report of the JGCA nationwide registry [J]. Gastric Cancer, 2013, 16(1):1-27.
|
| [4] |
Fushida S, Oyama K, Kinoshita J, et al. Intraperitoneal Chemotherapy as a Multimodal Treatment for Gastric Cancer Patients with Peritoneal Metastasis [J]. J Cancer Ther, 2013, 4(9A):6-15.
|
| [5] |
Yonemura Y, Bandou E, Kawamura T, et al. Quantitative prognostic indicators of peritoneal dissemination of gastric cancer [J]. Eur J Surg Oncol, 2006,32(6):602-606.
|
| [6] |
Dalkey N, Helmer O. An Experimental Application of the Delphi Method to the Use of Experts [J]. Manage Sci, 1963,9(3):458-467.
|
| [7] |
Atkins D, Best D, Briss PA, et al; GRADE Working Group. Grading quality of evidence and strength of recommendations [J]. BMJ, 2004,328(7454):1490.
|
| [8] |
Paget S. Distribution of secondary growths in cancer of the breast [J]. Cancer Metastasis Rev, 1989,8:98-101.
|
| [9] |
Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil’ hypothesis revisited [J]. Nat Rev Cancer, 2003, 3(6):453-458.
|
| [10] |
Ahmed N, Riley C, Rice G, et al. Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment[J]. Clin Exp Metastasis, 2005,22(5):391-402.
|
| [11] |
Miyazono K, Suzuki H, Imamura T. Regulation of TGF-beta signaling and its roles in progression of tumors [J]. Cancer Sci, 2003,94(3):230-234.
|
| [12] |
Al-Shammaa HA, Li Y, Yonemura Y. Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis [J]. World J Gastroenterol, 2008,14(8):1159-1166.
|
| [13] |
徐惠绵，武建华.胃癌腹膜转移机理及其临床应用的研究进展[J].中国肿瘤临床，2012，39(22):1687-1690.
|
| [14] |
Lim JS, Kim MJ, Yun MJ, et al. Comparison of CT and 18F-FDG pet for detecting peritoneal metastasis on the preoperative evaluation for gastric carcinoma [J]. Korean J Radiol, 2006, 7(4):249-256.
|
| [46] |
梁寒.胃癌腹膜转移的诊治策略[J].中国肿瘤临床，2012，39(22):1696-1698.
|
| [47] |
Yan TD, Black D, Sugarbaker PH, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer [J]. Ann Surg Oncol, 2007, 14(10):2702-2713.
|
| [48] |
Fujimoto S, Takahashi M, Mutou T, et al. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma [J]. Cancer, 1999,85(3):529-534.
|
| [49] |
朱正纲，汤睿，燕敏，等.术中腹腔内温热化疗对进展期胃癌的临床疗效研究[J].中华胃肠外科杂志，2006，9(1):26-30.
|
| [50] |
Pyrhönen S, Kuitunen T, Nyandoto P, et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer[J]. Br J Cancer, 1995 , 71(3):587-591.
|
| [51] |
Van Cutsem E, Moiseyenko VM, Tjulandin S, et al ; V325 Study Group. Phase Ⅲ study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group [J] . J Clin Oncol, 2006,24(31):4991-4997.
|
| [52] |
Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phaseⅢ trial [J]. Lancet Oncol, 2008 ,9(3):215-221.
|
| [53] |
Yamada Y, Higuchi K, Nishikawa K, et al. Phase Ⅲ study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer [J]. Ann Oncol, 2015,26(1):141-148.
|
| [54] |
Shirao K, Boku N, Yamada Y, et al; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Randomized Phase Ⅲ Study of 5-Fluorouracil Continuous Infusion vs. Sequential Methotrexate and 5-Fluorouracil Therapy in Far Advanced Gastric Cancer with Peritoneal Metastasis (JCOG0106) [J]. Jpn J Clin Oncol, 2013,43(10):972-980.
|
| [55] |
Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer : arandomised phase 3 study [J]. Lancet Oncol, 2009,10(11):1063-1069.
|
| [56] |
Fuchs CS, Tomasek J, Yong CJ, et al; REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junctionadeno carcinoma (REGARD) : an international, randomised, multicentre, placebo-controlled, phase 3 trial[J]. Lancet, 2014,383(9911):31-39.
|
| [57] |
Wilke H, Muro K, Van Cutsem E, et al; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advancedgastric or gastro-oesophageal junction adenocarcinoma ( RAINBOW) : a double-blind, randomised phase 3 trial [J]. Lancet Oncol, 2014, 15(11):1224-1235.
|
| [58] |
Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase Ⅲ study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum : WJOG 4007 trial [J]. J Clin Oncol, 2013,31(35):4438-4444.
|
| [59] |
Narahara H, Iishi H, Imamura H, et al. Randomized phase Ⅲstudy comparing the efficacy and safety of irinotecan plus S-1 with S-1alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002) [J]. Gastric Cancer, 2011,14(1):72-80.
|
| [60] |
Nishina T, Boku N, Gotoh M, et al; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versusweekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407) [J]. Gastric Cancer, 2016, 19(3):902-910.
|
| [61] |
Moehler M, Eimermacher A, Siebler J, et al. Randomised phase Ⅱ evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer[J]. Br J Cancer, 2005, 92(12):2122-2128.
|
| [62] |
Ishigami H, Fujiwara Y, Fukushima R, et al. Phase Ⅲ study of intraperitoneal paclitaxel plus S-1/paclitaxel compared with S-1/ cisplatin in gastric cancer patients with peritoneal metastasis: PHOENIX-GC trial [C]. Poster presented at 2016 ASCO Annual Meeting; 4 June 2016; Chicago, Illinois, USA.
|
| [63] |
李燕，李洁，张晓东，等.腹腔联合全身化疗治疗胃肠道恶性肿瘤并发腹腔积液81例[J].肿瘤研究与临床，2009，21(1):52-53.
|
| [64] |
黄万中，蒋华，刘燕文，等.多西紫杉醇腹腔灌注化疗治疗晚期胃癌Ⅱ期临床研究[J].现代肿瘤医学，2011，19(5):960-963.
|
| [65] |
李翔.紫杉醇腹腔灌注化疗治疗胃癌恶性腹腔积液的临床研究[J].江西医药，2015，50(5):390-393.
|
| [66] |
Fujitani K, Yang HK, Mizusawa J, et al; REGATTA study investigators. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA) : a phase 3, randomised controlled trial [J]. Lancet Oncol, 2016,17(3):309-318.
|
| [67] |
Feingold PL, Kwong ML, Sabesan A, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer and other less common disease histologies : is it time? [J]. J Gastrointest Oncol, 2016,7(1):87-98.
|
| [68] |
Sangisetty SL, Miner TJ. Malignant ascites : a review of prognostic factors, pathophysiology and therapeutic measures [J]. World J Gastrointest Surg, 2012,4(4):87-95.
|
| [69] |
Saif MW, Siddiqui IA, Sohail MA. Management of ascites due to gastrointestinal malignancy [J]. Ann Saudi Med, 2009,29(5):369-377.
|
| [70] |
Chang DK, Kim JW, Kim BK, et al. Clinical significance of CT-defined minimal ascites in patients with gastric cancer [J]. World J Gastroenterol, 2015, 11(42):6587-6592.
|
| [71] |
Maeda H, Kobayashi M, Sakamoto J. Evaluation and treatment of malignant ascites secondary to gastric cancer [J]. World J Gastroenterol, 2015,21(39):10936-10947.
|
| [72] |
Smith EM, Jayson GC. The current and future management of malignant ascites [J]. Clin Oncol (R Coll Radiol), 2003, 15(2):59-72.
|
| [73] |
O'Neill MJ, Weissleder R, Gervais DA, et al. Tunneled peritoneal catheter placement under sonographic and fluoroscopic guidance in the palliative treatment of malignant ascites [J] . AJR Am J Roentgenol, 2001, 177(3):615-618.
|
| [74] |
Barnett TD, Rubins J. Placement of a permanent tunneled peritoneal drainage catheter for palliation of malignant ascites : a simplified percutaneous approach [J]. J Vasc Interv Radiol, 2002, 13(4):379-383.
|
| [75] |
张岂凡，郑宏群，孙凌宇.胃癌腹腔转移所致恶性肠梗阻的诊治及营养支持策略[J].中国肿瘤临床，2014，41(12):749-752.
|
| [76] |
O'Connor B, Creedon B. Pharmacological treatment of bowel obstruction in cancer patients [J]. Expert Opin Pharmacother, 2011, 12(14):2205-2214.
|
| [77] |
Watari H, Hosaka M, Wakui Y, et al. A prospective study on the efficacy of octreotide in the management of malignant bowel obstruction in gynecologic cancer [J]. Int J Gynecol Cancer, 2012, 22(4):692-696.
|
| [78] |
Prommer E. Anticholinergics in palliative medicine : an update[J]. Am J Hosp Palliat Care, 2013 ,30(5):490-498.
|
| [79] |
Olson TJP, Pinkerton C, Brasel KJ, et al. Palliative surgery for malignant bowel obstruction from carcinomatosis : a systematic review [J]. JAMA Surg, 2014,149(4):383-392.
|
| [80] |
Kim JH, Ku YS, Jeon TJ, et al. The efficacy of self-expanding metal stents for malignant colorectal obstruction by noncolonic malignancy with peritoneal carcinomatosis [J]. Dis Colon Rectum, 2013,56(11):1228-1232.
|
| [81] |
Tuca A, Guell E, Martinez-Losada E, et al. Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution [J]. Cancer Manag Res, 2012, 4:159-169.
|
| [82] |
Iwasa S, Goto M, Yasui H, et al. Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake [J]. Jpn J Clin Oncol, 2012, 42(9):787-793.
|